WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H563126
CAS#: 1206711-14-9
Description: DMH2 is a bone morphogenetic protein (BMP) type I receptor antagonist. It acts by decreasing growth and inducing cell death of lung cancer cell lines.
Hodoodo Cat#: H563126
Name: DMH2
CAS#: 1206711-14-9
Chemical Formula: C27H25N5O2
Exact Mass: 451.20
Molecular Weight: 451.530
Elemental Analysis: C, 71.82; H, 5.58; N, 15.51; O, 7.09
Synonym: DMH2; DMH-2; DMH 2;
IUPAC/Chemical Name: 4-(2-(4-(3-(Quinolin-4-yl)pyrazolo[1,5-a]pyrimidin-6-yl)phenoxy)ethyl)morpholine
InChi Key: DXLXRNZCYAYUED-UHFFFAOYSA-N
InChi Code: InChI=1S/C27H25N5O2/c1-2-4-26-24(3-1)23(9-10-28-26)25-18-30-32-19-21(17-29-27(25)32)20-5-7-22(8-6-20)34-16-13-31-11-14-33-15-12-31/h1-10,17-19H,11-16H2
SMILES Code: N1(CCOC2=CC=C(C3=CN4C(N=C3)=C(C5=CC=NC6=CC=CC=C56)C=N4)C=C2)CCOCC1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 451.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Newman JH, Augeri DJ, NeMoyer R, Malhotra J, Langenfeld E, Chesson CB, Dobias NS, Lee MJ, Tarabichi S, Jhawar SR, Bommareddy PK, Marshall S, Sadimin ET, Kerrigan JE, Goedken M, Minerowicz C, Jabbour SK, Li S, Carayannopolous MO, Zloza A, Langenfeld J. Novel bone morphogenetic protein receptor inhibitor JL5 suppresses tumor cell survival signaling and induces regression of human lung cancer. Oncogene. 2018 Apr 6. doi: 10.1038/s41388-018-0156-9. [Epub ahead of print] PubMed PMID: 29622797.
2: Tsugawa D, Oya Y, Masuzaki R, Ray K, Engers DW, Dib M, Do N, Kuramitsu K, Ho K, Frist A, Yu PB, Bloch KD, Lindsley CW, Hopkins CR, Hong CC, Karp SJ. Specific activin receptor-like kinase 3 inhibitors enhance liver regeneration. J Pharmacol Exp Ther. 2014 Dec;351(3):549-58. doi: 10.1124/jpet.114.216903. Epub 2014 Sep 30. PubMed PMID: 25271257; PubMed Central PMCID: PMC4244585.
3: Langenfeld E, Deen M, Zachariah E, Langenfeld J. Small molecule antagonist of the bone morphogenetic protein type I receptors suppresses growth and expression of Id1 and Id3 in lung cancer cells expressing Oct4 or nestin. Mol Cancer. 2013 Oct 26;12(1):129. doi: 10.1186/1476-4598-12-129. PubMed PMID: 24160469; PubMed Central PMCID: PMC4176118.
4: Langenfeld E, Hong CC, Lanke G, Langenfeld J. Bone morphogenetic protein type I receptor antagonists decrease growth and induce cell death of lung cancer cell lines. PLoS One. 2013 Apr 12;8(4):e61256. doi: 10.1371/journal.pone.0061256. Print 2013. PubMed PMID: 23593444; PubMed Central PMCID: PMC3625205.
